Dr. Chuanhui Xu and Dr. Xiuru Wang contribute equally to this work.
Societal costs of rheumatoid arthritis in China: A hospital-based cross-sectional study
Copyright © 2013 American College of Rheumatology
- Accepted manuscript online: 10 SEP 2013 03:31PM EST
- Manuscript Accepted: 3 SEP 2013
- Manuscript Revised: 7 AUG 2013
- Manuscript Received: 17 FEB 2013
- National Basic Research Program of China (973 Program). Grant Number: 2010CB529104
- National Natural Science Foundation of China. Grant Number: 81072401
- Cited By
- Rheumatoid arthritis;
Objective: To estimate the annual direct and indirect costs of rheumatoid arthritis (RA) in China, and identify the predictors for cost-of-illness.
Methods: A cross-sectional study of cost-of-illness was conducted on 829 patients with RA in 21 tertiary care hospitals in China between July 2009 and December 2010 from the societal perspective. Data on demographics, clinical variables, and components of costs were collected by physician interview. Costs were represented in 2009 US dollars ($) using purchasing power parity estimates. Univariate and multivariate linear regression analyses were performed to identify the predictors for cost-of-illness.
Results: The mean (S.D.) total costs of RA were $3,826 (5,659) per patient-year in China, given GDP per capita of $6,798 in China in 2009. Direct costs and indirect costs comprised 90.0% and 10.0% of the total costs, respectively. Drug expense represented approximately half of total costs, dominated by biologics (48.2%) and DMARDs (23.6%). Besides, the costs of extracted herbal drugs and traditional Chinese medicine were about 17.6% of drug expense. Higher education level, non-insured status, longer disease duration, more extra-articular manifestations, and higher HAQ score independently predicted higher total costs.
Conclusion: Our results provide the first study of costs of RA in China. This study not only demonstrates the economic burden of RA, but also identifies the predictors that could be interventional factors to reduce the societal costs of RA in China. © 2013 American College of Rheumatology.